Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the American markets (Argentina, Canada, Chile, Colombia and Peru). We report both the incidence and prevalence of IPF for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s IPF forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of IPF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 11 IPF patient populations, as follows:
Diagnosed incident cases of IPF.
Diagnosed prevalent cases of IPF.
Diagnosed prevalent cases of stage 1 IPF.
Diagnosed prevalent cases of stage 2 IPF.
Diagnosed prevalent cases of stage 3 IPF.
Diagnosed prevalent cases of IPF with gastroesophageal reflux disease.
Diagnosed prevalent cases of IPF with emphysema.
Diagnosed prevalent cases of IPF with pulmonary hypertension.
Diagnosed prevalent cases of IPF with obstructive sleep apnea.
Diagnosed drug-treated prevalent cases of IPF.
Diagnosed non-drug-treated prevalent cases of IPF.
Literature review (studies included in/excluded from the analyses of idiopathic pulmonary fibrosis)
Diagnosed prevalent cases of idiopathic pulmonary fibrosis
Diagnosed incident cases of idiopathic pulmonary fibrosis
Diagnosed prevalent cases of idiopathic pulmonary fibrosis by severity
Diagnosed prevalent cases of idiopathic pulmonary fibrosis with gastroesophageal reflux disease
Diagnosed prevalent cases of idiopathic pulmonary fibrosis with pulmonary hypertension
Diagnosed prevalent cases of idiopathic pulmonary fibrosis with emphysema
Diagnosed prevalent cases of idiopathic pulmonary fibrosis with obstructive sleep apnea
Drug-treated prevalent cases of idiopathic pulmonary fibrosis
Risk/protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation table
Mohani Latwal
Mohani Latwal, B.P.T., M.P.H., is an associate epidemiologist at Clarivate. She received her bachelor’s degree in physiotherapy from Delhi University and her master’s degree in public health with a specialization in social epidemiology from the Tata Institute of Social Sciences in Mumbai. Prior to joining Clarivate, she worked as a deputy manager at an NGO.
Surup Dey
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.
